Skip to main content
. 2014 May 20;10(8):1391–1402. doi: 10.4161/auto.29119

Table 3. RECIST response in evaluable patients.

HCQ dose cohort N PR SD PD NE
Phase I dose escalation
200 6 0 4 2 5
400 3 0 3 0 0
800 9 0 5 4 0
1200 3 0 2 1 0
Total 21 0 (0%) 14 (67%) 7 (33%) 5
Melanoma patients
200–800 6 0 5 1 2
1200 13 0 9 4 1
Total 19 0 14 (74%) 5 (26%) 3

PR, Partial response; SD, stable disease; PD, progressive disease; NE, not evaluable